CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating ...

The Phase 1 SPARC trial evaluates safety, tolerability, and pharmacokinetics across multiple OPT101 concentrations during ...

Agilent Technologies, Inc. (NYSE:A) is one of the 10 best life sciences stocks to buy according to hedge funds. On February ...

Can artificial intelligence (AI) tools reliably handle the complexity and nuance of cancer care? A new systematic evaluation from Shanghai places that question under rigorous clinical scrutiny, ...

The efficacy and safety of donafenib-containing regimens as postoperative adjuvant therapy for hepatocellular carcinoma (HCC): A multicenter retrospective study. This is an ASCO Meeting Abstract from ...

Johnson & Johnson's stock hits a 52-week high, but key drug patent risks and a lower Wall Street price target suggest downside. Learn more about JNJ stock here.

Researchers used genome-wide CRISPR screens to identify genetic diseases responsive to vitamins B2 and B3. In mice lacking ...

Leading US liver transplant center completes its first two implantationsMount Sinai Hospital and University of Pennsylvania also complete multiple implantations ...

By the 1890s, just as the medical world was beginning to understand that invisible microbes caused infectious diseases, the idea that a missing ...

At age 66, Richard "Dick" Nash first suspected something might be wrong when he participated in a Dallas walk for juvenile ...

Ghent, Belgium, 26 February 2026 - Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

Researchers at Nagoya University have reported that ovarian cancer cells form hybrid clusters with mesothelial cells in abdominal fluid, a process that appears to accelerate tissue invasion and ...